Insider Watch: Cook Doubles Down on Nike as Activists Strike Genesco

Apple CEO Tim Cook bought 25,000 Nike shares for $1.06 million on April 10, his second post-earnings purchase in two quarters.

This week’s insider activity told two stories at once. CEOs at the top of the corporate food chain wrote personal checks for their own stock, while smaller activist funds disclosed positions large enough to force a board conversation. Both signals run through the same SEC plumbing. Both deserve attention from anyone watching where sophisticated capital actually went in April.

Tim Cook Buys More Nike Right After Earnings. Again.

Apple CEO Tim Cook bought 25,000 shares of Nike on April 10, paying $42.43 per share for a total of $1,060,750. Three days later, Nike CEO Elliott Hill bought 23,660 Class B shares of his own company at $42.265, spending $999,999. Both purchases were disclosed on Form 4 (the SEC filing executives and directors must submit within two business days when they buy or sell their own company’s stock). Both landed in the same week as Nike’s fiscal Q3 earnings print.

The pattern is what stands out. Cook also bought Nike immediately after the company’s previous earnings, and Hill matched him then too. Two consecutive post-earnings cluster buys from a sitting CEO and a high-profile board member is rare. It points at a deliberate signal rather than an opportunistic dip purchase.

Nike stock closed near $45.70 on April 17, down roughly 30% year to date and 36% over six months. The 52-week low is $42.09, set days before Cook’s purchase. CNBC framed the buy as “a much-needed vote of confidence” amid Nike’s turnaround under Hill, who took the CEO seat in October 2024.

Two Activists Take a $24 Million Position in Genesco

Bradley Radoff, a Houston-based private investor, and Christopher Martin’s Jumana Capital Investments filed a joint Schedule 13D on Genesco on April 15. A Schedule 13D (the SEC disclosure required within 10 days when an investor crosses 5% of a public company AND intends to influence its management or strategy) reveals both the size of the stake and the filer’s stated intent. The Radoff and Jumana group disclosed 830,000 shares, or 7.6% of Genesco, a roughly $24 million combined position at recent prices.

The intent language is direct. The group called the shares “undervalued” and said it plans to “engage constructively with the Issuer’s Board of Directors and management team regarding opportunities to unlock value.” The filing then lists the specific levers under consideration: changes to the board’s composition, capital allocation, capitalization, ownership structure, and “the sale of the Issuer as a whole or in parts.”

Genesco owns the Journeys, Schuh, and Johnston & Murphy footwear chains. The stock traded near $34.65 on April 16 after a 3% jump on the disclosure. Radoff has a track record in small-cap activism, with prior campaigns at Adams Resources & Energy and other mid-cap names.

Shah Capital Pushes Novavax to Cut, Shrink, and Possibly Sell

Shah Capital Management filed a Schedule 13D amendment on Novavax on April 8 alongside a public letter to the board. The fund disclosed a 9.11% stake, equal to 14,845,097 shares, and laid out a sharp list of demands.

The asks: cut senior management by 30%, shrink the board from eight members to five, and execute a 10 to 20 million share buyback. Shah cited “value destruction,” a “pessimistic 2026 Revenue forecast,” and “low institutional credibility” as the basis for the campaign. The fund also said it will vote against the board’s nominees and the executive compensation package at the next annual meeting, while acknowledging it will “be in minority against an entrenched eight-member board.”

Shah did not file proxy materials for a dissident director slate. The campaign so far is a public pressure play, not a full board fight. It does add a biotech angle to a week otherwise dominated by retail and consumer activist activity.

An Energy Chairman Buys Into His Own Secondary

Tom Ward, chairman and CEO of MACH Natural Resources and the former CEO of Chesapeake Energy and SandRidge, bought 153,256 units of MACH on April 13 for roughly $2 million through two controlled entities. The unit price of $13.05 matched the price of MACH’s just-closed 9-million-unit secondary offering, which priced on April 8.

The structure matters. A secondary offering (a public company selling additional shares to raise new capital, which typically dilutes existing holders) usually pulls insiders to the sidelines. An insider buying at the offering price alongside outside investors is the opposite signal. Ward now holds about 28 million units across his various entities. MACH closed near $12.65 on April 16, down 5% over twelve months.

The Number That Matters

$24 million. That is what the Radoff and Jumana group put on the table at Genesco, not as paper exposure or option value, but as cash cost basis in a small-cap retailer with a market capitalization near $400 million. The size of the commitment relative to the company is what gives the campaign teeth. A 7.6% holder pushing publicly for a sale process is harder for a board to ignore than a 1% holder writing a letter. That makes Genesco the activist situation most worth tracking through the next quarterly cycle.

What to Watch

Nike Q4 earnings: Whether Cook and Hill make a third consecutive post-earnings buy will tell investors whether the pattern is structural conviction or a stabilizing gesture for the stock.

Genesco board response: The Radoff and Jumana letter explicitly raises a sale process. Watch for whether the Genesco board engages, deflects, or adopts a poison pill (a defensive corporate measure that lets existing shareholders buy more stock at a discount when an acquirer crosses a threshold, designed to deter hostile bids) in the next 30 days.

Novavax annual meeting: Shah Capital’s “no” vote on directors and pay is a warm-up. The percentage of unaffiliated shares that vote with Shah will determine whether a real proxy fight follows in 2027.